Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Evaluation of the Effect of Simvastatin Therapy on Bone Remodeling in Rats


Affiliations
1 Master Student, Department of Pharmacology and Toxicology, Tishreen University, Latakia,, Syrian Arab Republic
2 Professor, Department of Pharmacology and Toxicology, Tishreen University, Latakia,, Syrian Arab Republic
     

   Subscribe/Renew Journal


Objective: The aim of this study was to evaluate the effect of simvastatin on the bone remolding markers in rats (experimental study). Materials and methods: The study involved 18 male Wistar rats, they were divided into three groups: Group I (n=6; control group), Group II (n=6; was administrated 7.5 mg/kg/ dexamethasone intra muscular for 2 months served as a model of osteoporosis [op]), Group III (n=6;was administered 7.5 mg/kg/ dexamethasone intra muscular for 2month and treated orally with 8mg/kg of simvastatin).After 8 weeks, serum acid phosphatase was determined for the three group. Results: The levels of serum acid phosphatase were notably elevated in the [op] group. Administration of simvastatin produced a significant decrease in the levels of serum acid phosphatase. Conclusion: simvastatin was able to decrease the rate of bone resorption in an animal model of osteoporosis induced by dexamethasone.

Keywords

Statins, Simvastatin, Osteoporosis, ACP, Bone resorption.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Sakat Bhagyashri T. Sakhare R B. Suryvanshi U C. Kore P S. Mohite S K. Magdum C S. Osteoporosis: The Brittle Bone. Asian J. Pharm. Res. 2018; 8(1):39-43. doi: 10.5958/2231-5691.2018.00008.4
  • Chitra V. Mohammed Anwar Ali M. Animal Models for Osteoporosis-A Review. Research J. Pharm. and Tech 2020; 13(3):1543-1548. doi.org/10.5958/0974-360X.2020.00280.2
  • Famili P. Cauley J. Suzuki JB. Weyant R Longitudinal study of periodontal disease and edentulism with rates of bone loss in older women. J Periodontol. 2005; 76(1):11–15. doi.org /10.1902/jop.2005.76.1.11
  • O’Neill TW. Felsenberg D. Varlow J. Cooper C. Kanis JA. Silman AJ The prevalence of vertebral deformity in European men and women: the European vertebral osteoporosis study. J Bone Miner Res. 1996; 11(7):1010–1018. doi.org/10.1002/jbmr.5650110719
  • Khoshnood Z. Anoosheh M. Haji Zadej E A Description of Osteoporosis Preventive Behaviors in Iranian Adolescent Girls. Asian J. Nur. Edu. and Research. 2016; 6(1): 1-4. doi: 10.5958/2349-2996.2016.00001.X
  • Zerzour .A Haddig N. Derouiche S Analysis of Osteoporosis risk factors in Menopausal women's of Algeria population. Asian J. Res. Pharm. Sci. 2020; 10(2):79-84. doi.org/10.5958/2231-5659.2020.00015.6
  • Rossini M. Adami S. Bertoldo F et al Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo. 2016; 68(1):1–39. doi.org/ 10.4081/reumatismo.2016.870
  • Radhakrishna B. Ashok M. Harish PL. Veera Jyothsna M. Shivalinge Gowda KP Current and Future Trends of Drugs Used in Osteoporosis. Research J. Pharmacology and Pharmacodynamics. 2011; 3(6): 329-333.
  • Hajime M. Okada Y. Mori H. Tanaka Y A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab. 2014; 32(5):601–604. doi.org/10.1007/s00774-014-0564-z
  • Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int. 2010; 86(6):421–435. doi.org/10.1007/s00223-010-9364-1
  • Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009; 8(2):96–110. doi.org/ 10.14310/horm.2002.1226
  • Moraes LA. Vaiyapuri S. Sasikumar P et al Antithrombotic actions of statins involve PECAM-1 signaling. Blood. 2013;122(18):3188–3196. doi.org/10.1182/blood-2013-04-491845
  • Hatzigeorgiou C. Jackson JL. Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int. 2005;16(8):990–998. doi.org/10.1007/s00198-004-1793-0
  • Ganesh Akula. Bollaboina Venkatesh. Sanjayraj K. Phanindra S S. Jaswanth A. Validated RP-HPLC Method for the Simultaneous Estimation of Simvastatin and Niacin. Asian J. Research Chem. 9(2): Feb., 2016; Page 62-66. doi: 10.5958/0974-4150.2016.00011.0
  • Nakkala Balaji. Sai Kishore V. Kasani Hari Krishna Gouda. Formulation and Evaluation of Simvastatin Solid Dispersions for Dissolution Rate Enhancement. Research J. Pharma. Dosage Forms and Tech. 2011; 3(4): 152-156.
  • Abdul Sayeed. Sheshgiri Gada. Mallikarjun B K Formulation and Development of Gastric Floating Drug Delivery Systems of Simvastatin. Research J. Pharm. and Tech.3 (4): Oct.-Dec.2010; Page 1252-1259.

Abstract Views: 97

PDF Views: 0




  • Evaluation of the Effect of Simvastatin Therapy on Bone Remodeling in Rats

Abstract Views: 97  |  PDF Views: 0

Authors

Sami Ali
Master Student, Department of Pharmacology and Toxicology, Tishreen University, Latakia,, Syrian Arab Republic
Rana Makhous
Professor, Department of Pharmacology and Toxicology, Tishreen University, Latakia,, Syrian Arab Republic

Abstract


Objective: The aim of this study was to evaluate the effect of simvastatin on the bone remolding markers in rats (experimental study). Materials and methods: The study involved 18 male Wistar rats, they were divided into three groups: Group I (n=6; control group), Group II (n=6; was administrated 7.5 mg/kg/ dexamethasone intra muscular for 2 months served as a model of osteoporosis [op]), Group III (n=6;was administered 7.5 mg/kg/ dexamethasone intra muscular for 2month and treated orally with 8mg/kg of simvastatin).After 8 weeks, serum acid phosphatase was determined for the three group. Results: The levels of serum acid phosphatase were notably elevated in the [op] group. Administration of simvastatin produced a significant decrease in the levels of serum acid phosphatase. Conclusion: simvastatin was able to decrease the rate of bone resorption in an animal model of osteoporosis induced by dexamethasone.

Keywords


Statins, Simvastatin, Osteoporosis, ACP, Bone resorption.

References